ALSO READLondon-listed drugmaker Indivior shares crash after U.S. patent blow Dr Reddy's gets favourable verdict on patent litigation of drug Suboxone Swamy's PIL stands for 'Publicity Interest Litigation': Menon's counsel Vizag 'land scam': Runaway revenue official held in Hyd Andhra Revenue Department way ahead in tech reforms: Dy CM Murthy
REUTERS - Indivior said on Friday its U.S. subsidiary has filed patent lawsuits against firms seeking approval for generic versions of its opioid addiction treatment Suboxone, which generates 80 percent of Indivior's revenue.
The lawsuits were filed against Dr. Reddy's, Allergan Plc's Actavis Laboratories, Endo International's Par Pharmaceutical, Alvogen Pharma US, Teva Pharmaceutical Industries and Mylan NV.
The lawsuits allege that these companies have infringed a patent that relates to an oral film containing buprenorphine and naloxone, the London-listed drugmaker said in a statement.
(Reporting by Justin George Varghese in Bengaluru; editing by David Clarke)
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)